+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Endoscopic Retrograde Cholangiopancreatography/ERCP Market Size, Share & Industry Trends Analysis Report By Procedure, By Product, By Endotherapy Devices Type, By End User, By Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 120 Pages
  • April 2022
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5600659
The Latin America, Middle East and Africa Endoscopic Retrograde Cholangiopancreatography Market is expected to witness market growth of 15.0% CAGR during the forecast period (2022-2028).

The use of precut sphincterotomy incorporating sphincterotomy for cases with difficult biliary access must be done immediately to minimize this risk. For patients with severe conditions, Ogilvie syndrome is characterized by severe colon dilatation in the presence of any mechanical barrier.

The esophageal diverticula's position in the oesophagus is used to classify the condition. Zenker's diverticula are the most frequent source of esophageal diverticula. Endoscopic retrograde cholangiopancreatography (ERCP) is an important tool for hepatobiliary system diagnosis and treatment. & nbsp;
In terms of appearance and diagnostic precision, magnetic resonance cholangiopancreatography (MRCP) is a novel non-invasive modality that projects liquid in the biliary and pancreatic ducts in an axial or three-dimensional image format, comparable to radiographic methods seen with direct contrast endoscopic retrograde cholangiopancreatography (ERCP).

A large number of gallbladder procedures, an increase in pancreatic disorders in Brazil, and a growing geriatric population base are expected to drive growth in the regional Market over the coming years. Due to factors such as a large number of gallbladder surgeries in Saudi Arabia, the United Arab Emirates, and South Africa, as well as an increase in pancreatic diseases coupled with high healthcare expenditures in the Middle Eastern countries. Over the next several years, the endoscopic retrograde cholangiopancreatography devices Market will be driven by robust product pipeline activity.

As part of its economic portfolio, the UAE has invested a lot in the establishment of world-class medical facilities, with high treatment standards for UAE citizens as well as visitors from other nations, particularly from the Middle East and Africa, who come to the UAE on medical tourist visas. According to the World Health Organization, one-third of adults in the UAE are obese, and one out of every five persons has diabetes. As the prevalence of lifestyle diseases rises, these people is expected to require higher-quality healthcare. To meet this demand, the government is emphasizing on strengthening healthcare infrastructure and this factor is expected to increase the adoption of endoscopic devices across the region.

The Brazil Market dominated the LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $58.8 million by 2028. The Argentina Market is estimated to grow at a CAGR of 15.6% during (2022-2028). Additionally, The UAE Market is expected to display a CAGR of 14.6% during (2022-2028).

Based on Procedure, the Market is segmented into Biliary Sphincterotomy, Biliary Stenting, Biliary Dialatation, Pancreatic Sphincterotomy, and Pancreatic Duct Stenting & Dilation. Based on Product, the Market is segmented into Endotherapy Devices, Endoscopes, Visualization Systems, Energy Devices, and Others. Based on Endotherapy Devices Type, the Market is segmented into Stents & Sphincterotomes, Catheters, Lithotripter, Cannulas, Forceps, Snares, Guiding Wires, Balloons, and Others. Based on End user, the Market is segmented into Hospitals, Ambulatory Surgery Centres & Clinics, and Others. Based on countries, the Market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Olympus Corporation, Fujifilm Holdings Corporation, Ambu A/S, Boston Scientific Corporation, Steris PLC, Johnson & Johnson, B. Braun Melsungen AG, ConMed Corporation, Medtronic PLC, and Karl Storz SE & Co. KG.

Scope of the Study


Market Segments Covered in the Report:


By Procedure
  • Biliary Sphincterotomy
  • Biliary Stenting
  • Biliary Dialatation
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Stenting & Dilation
By Product
  • Endotherapy Devices
    • Stents & Sphincterotomes
    • Catheters
    • Lithotripter
    • Cannulas
    • Forceps
    • Snares
    • Guiding Wires
    • Balloons
    • Others
  • Endoscopes
  • Visualization Systems
  • Energy Devices
  • Others
By End User
  • Hospitals
  • Ambulatory Surgery Centres & Clinics
  • Others

By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • Olympus Corporation
  • Fujifilm Holdings Corporation
  • Ambu A/S
  • Boston Scientific Corporation
  • Steris PLC
  • Johnson & Johnson
  • Braun Melsungen AG
  • ConMed Corporation
  • Medtronic PLC
  • Karl Storz SE & Co. KG

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Endoscopic Retrograde Cholangiopancreatography Market, by Procedure
1.4.2 LAMEA Endoscopic Retrograde Cholangiopancreatography Market, by Product
1.4.3 LAMEA Endoscopic Retrograde Cholangiopancreatography Market, by End User
1.4.4 LAMEA Endoscopic Retrograde Cholangiopancreatography Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Endoscopic Retrograde Cholangiopancreatography/ERCP Market
Chapter 4. LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Procedure
4.1 LAMEA Biliary Sphincterotomy Market by Country
4.2 LAMEA Biliary Stenting Market by Country
4.3 LAMEA Biliary Dialatation Market by Country
4.4 LAMEA Pancreatic Sphincterotomy Market by Country
4.5 LAMEA Pancreatic Duct Stenting & Dilation Market by Country
Chapter 5. LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Product
5.1 LAMEA Endotherapy Devices Market by Country
5.2 LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
5.2.1 LAMEA Stents & Sphincterotomes Market by Country
5.2.2 LAMEA Catheters Market by Country
5.2.3 LAMEA Lithotripter Market by Country
5.2.4 LAMEA Cannulas Market by Country
5.2.5 LAMEA Forceps Market by Country
5.2.6 LAMEA Snares Market by Country
5.2.7 LAMEA Guiding Wires Market by Country
5.2.8 LAMEA Balloons Market by Country
5.2.9 LAMEA Others Market by Country
5.3 LAMEA Endoscopes Market by Country
5.4 LAMEA Visualization Systems Market by Country
5.5 LAMEA Energy Devices Market by Country
5.6 LAMEA Others Market by Country
Chapter 6. LAMEA Endoscopic Retrograde Cholangiopancreatography Market by End User
6.1 LAMEA Hospitals Market by Country
6.2 LAMEA Ambulatory Surgery Centres & Clinics Market by Country
6.3 LAMEA Others Market by Country
Chapter 7. LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Country
7.1 Brazil Endoscopic Retrograde Cholangiopancreatography Market
7.1.1 Brazil Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.1.2 Brazil Endoscopic Retrograde Cholangiopancreatography Market by Product
7.1.2.1 Brazil Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.1.3 Brazil Endoscopic Retrograde Cholangiopancreatography Market by End User
7.2 Argentina Endoscopic Retrograde Cholangiopancreatography Market
7.2.1 Argentina Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.2.2 Argentina Endoscopic Retrograde Cholangiopancreatography Market by Product
7.2.2.1 Argentina Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.2.3 Argentina Endoscopic Retrograde Cholangiopancreatography Market by End User
7.3 UAE Endoscopic Retrograde Cholangiopancreatography Market
7.3.1 UAE Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.3.2 UAE Endoscopic Retrograde Cholangiopancreatography Market by Product
7.3.2.1 UAE Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.3.3 UAE Endoscopic Retrograde Cholangiopancreatography Market by End User
7.4 Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market
7.4.1 Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.4.2 Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market by Product
7.4.2.1 Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.4.3 Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market by End User
7.5 South Africa Endoscopic Retrograde Cholangiopancreatography Market
7.5.1 South Africa Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.5.2 South Africa Endoscopic Retrograde Cholangiopancreatography Market by Product
7.5.2.1 South Africa Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.5.3 South Africa Endoscopic Retrograde Cholangiopancreatography Market by End User
7.6 Nigeria Endoscopic Retrograde Cholangiopancreatography Market
7.6.1 Nigeria Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.6.2 Nigeria Endoscopic Retrograde Cholangiopancreatography Market by Product
7.6.2.1 Nigeria Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.6.3 Nigeria Endoscopic Retrograde Cholangiopancreatography Market by End User
7.7 Rest of LAMEA Endoscopic Retrograde Cholangiopancreatography Market
7.7.1 Rest of LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Procedure
7.7.2 Rest of LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Product
7.7.2.1 Rest of LAMEA Endoscopic Retrograde Cholangiopancreatography Market by Endotherapy Devices Type
7.7.3 Rest of LAMEA Endoscopic Retrograde Cholangiopancreatography Market by End User
Chapter 8. Company Profiles
8.1 Olympus Corporation
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Product Launches and Product Expansions:
8.1.5.2 Approvals and Trials:
8.2 Fujifilm Holdings Corporation
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.3 Ambu A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segment & Regional Analysis
8.3.4 Recent strategies and developments:
8.3.4.1 Approvals and Trials:
8.4 Boston Scientific Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.5 Steris PLC
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.6 Johnson & Johnson
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental &Regional Analysis
8.6.4 Research & Development Expenses
8.7 B. Braun Melsungen AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.8 ConMed Corporation
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 Medtronic PLC
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.10. Karl Storz SE & Co. KG
8.10.1 Company Overview

Companies Mentioned

  • Olympus Corporation
  • Fujifilm Holdings Corporation
  • Ambu A/S
  • Boston Scientific Corporation
  • Steris PLC
  • Johnson & Johnson
  • B. Braun Melsungen AG
  • ConMed Corporation
  • Medtronic PLC
  • Karl Storz SE & Co. KG

Methodology

Loading
LOADING...